HTX-034
Total Payments
$1.2M
Transactions
17
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.2M | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Dose-Escalation Study of HTX-034 Following Bunionectomy | Heron Therapeutics, Inc. | $1.2M | 0 |
Top Doctors Receiving Payments for HTX-034
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $1.2M | 17 |
Ad
Manufacturing Companies
- Heron Therapeutics, Inc. $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 0
- Transactions 17
About HTX-034
HTX-034 is a drug associated with $1.2M in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Heron Therapeutics, Inc..
Payment data is available from 2020 to 2020. In 2020, $1.2M was paid across 17 transactions to 0 doctors.
The most common payment nature for HTX-034 is "Unspecified" ($1.2M, 100.0% of total).
HTX-034 is associated with 1 research study, including "Dose-Escalation Study of HTX-034 Following Bunionectomy" ($1.2M).